Imugene has signed a strategic partnership with NeoImmuneTech (NIT) to analyse its allogeneic CAR T cell therapy, azer-cel, along with the latter’s NT-I7 (efineptakin alfa) to treat cancer.
An allogeneic CD19 CAR T cell therapy programme, azer-cel has shown clinically meaningful activity with a suitable safety profile in blood cancers including lymphoma and leukaemia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A long-acting immune T cell amplifier Fc-fused recombinant human interleukin-7 cytokine, NT-I7 is at the clinical development stage.
The companies will assess the potential of NT-I7 in boosting the azer-cel allogeneic CAR T cells for each batch during the manufacturing process.
As part of preclinical work, the combination of azer-cel plus NT-I7 in intensifying the quantity and cancer-fighting characteristics of patients’ T cells during azer-cel treatment will be evaluated.
Imugene managing director and CEO Leslie Chong stated: “We are delighted to be working with NIT on the potential to enhance azer-cel activity as part of this research collaboration.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partnership is effective immediately and will be in place for two years.
Related research works will be conducted exclusively in the US.
Imugene will finance its portion of the deal through its currently scheduled research activities.
No further funding from Imugene is needed to carry out the initial work.
Each company owns the complete intellectual property (IP) rights to their respective background technology.
NIT and Imugene will hold talks regarding the generation of new IP rights from the deal.
NeoImmuneTech president and CEO Dr Se Hwan Yang stated: “NT-I7 has already shown encouraging results in multiple indications in immuno-oncology and infectious diseases, both as a monotherapy or in combination.
“The research collaboration with Imugene, an industry leader in allogeneic cell therapy, could greatly expand the potential of our asset and accelerate its path to commercialisation, as we did in acute radiation syndrome.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
